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ABSTRACT
OBJECTIVE: To estimate the seroprevalence of SARS-CoV-2 in the state of Maranhão, Brazil.
METHODS: A population-based household survey was performed, from July 27, 2020 to August 
8, 2020. The estimates considered clustering, stratification and non-response. Qualitative 
detection of IgM and IgG antibodies was performed in a fully-automated Elecsys® 
Anti-SARS-CoV-2 electrochemiluminescence immunoassay on the Cobas® e601 analyzer 
(Roche Diagnostics).
RESULTS: In total, 3,156 individuals were interviewed. Seroprevalence of total antibodies against 
SARS-CoV-2 was 40.4% (95%CI 35.6-45.3). Population adherence to non-pharmaceutical interventions 
was higher at the beginning of the pandemic than in the last month. SARS-CoV-2 infection rates 
were significantly lower among mask wearers and among those who maintained social and physical 
distancing in the last month compared to their counterparts. Among the infected, 26.0% were 
asymptomatic. The infection fatality rate (IFR) was 0.14%, higher for men and older adults. The IFR 
based on excess deaths was 0.28%. The ratio of estimated infections to reported cases was 22.2.
CONCLUSIONS: To the best of our knowledge, the seroprevalence of SARS-CoV-2 estimated in 
this population-based survey is one of the highest reported. The local herd immunity threshold 
may have been reached or might be reached soon.
DESCRIPTORS: Seroepidemiologic Studies. Coronavirus Infections. Immunity, Herd. Mortality.
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INTRODUCTION
Brazil is one of the countries most severely affected by the coronavirus disease 2019 (COVID-19) 
pandemic. By September 21, 2020, 4,558,040 cases were reported, with 137,272 deaths1. The 
national response has been controversial, testing capacity is low, and disagreements among 
the different levels of government over social distancing measures conveyed contradictory 
messages to the population. As a middle-income country, Brazil has high poverty rates and an 
extensive part of its population is engaged in informal activities that face difficulties to make 
ends meet and to follow stay-at-home measures2. As a consequence of all these facts, social 
distancing has not reached levels sufficient to curb and contain the COVID-19 pandemic3.
The state of Maranhão is located in the Northeast region of Brazil and has a population of 
7,114,598 inhabitants in 20204, with an area of 329,642 km², a little larger than that of Italy. It is 
one of the states in Brazil, where the pandemic gathered speed early. Its first case was reported 
on March 20, 2020, and by September 21, 2020 the number of deaths reported was 3,664. Deaths 
peaked in May and decreased thereafter. From May 3, 2020 to May 17, 2020, São Luís Island, 
where the state capital city is located, was put into lockdown. Reduction of social mobility 
reached at most 55% at the end of March and during lockdown at the capital, remaining low 
(40%–45%) during the worst phase of the pandemic. Despite low home quarantine adherence, 
the number of deaths decreased, and intensive care units occupancy diminished5.
Herd immunity threshold to attain control of severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) is an ongoing debate. Although some consider it to be around 
60%–70%, using the classical formula 1–1/R0, in which R0 is the basic reproductive number
6, 
other reports have proposed that herd immunity could be as low as 10%–20%7 or around 
43%8, due to the heterogeneity in susceptibility or exposure to infection across population 
groups7,8. However, reported population-based seroprevalences of SARS-CoV-2 were lower 
than the herd immunity thresholds, ranging from extremely low infections rates, close to 
1%–3%9,10, to values as high as 14.3% in Barcelona11, Spain, and 22.7% in New York City12. In 
Brazil, the highest reported population-based seroprevalences were 17.9%, for the São Paulo 
municipality13, and 66% for Manaus, where herd immunity may have played an important 
role in stablishing the size of the epidemic14.
The infection fatality rate (IFR) and the percentage of asymptomatic infections of 
SARS-CoV-2 are known with uncertainty. Early reports at the beginning of the pandemic 
estimated IFR at values between 0.6% and 1.3%15,16, and considered asymptomatic infections 
as being highly prevalent15,17. Most recent reviews, however, estimated a lower IFR with large 
variations across sites10,18 and a much lower percentage of asymptomatic infections11,19,20.
Population-based surveys are necessary to monitor the infection progression, since most 
cases are undocumented21. However, few population-based studies on the prevalence of 
SARS-CoV-2 have been performed, especially in low and middle-income countries. In this 
population-based study, we estimated the overall seroprevalence of SARS-CoV-2 using a 
serum testing electrochemiluminescence immunoassay. Sociodemographic characteristics 
of the population, self-reported symptoms, adherence to non-pharmaceutical interventions 
(NPI), use of health services, previous molecular and antibody testing among the infected, 
and the IFR were also assessed.
METHODS
Study Design and Participants
A cross-sectional survey to estimate the seroprevalence of antibodies against SARS-CoV-2 was 
conducted from July 27, 2020 to August 8, 2020 by population-based household sampling, 
in cooperation between the Universidade Federal do Maranhão and the Secretaria de Saúde 
do Estado do Maranhão, Brazil. 
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Conglomerate sampling in three stratified stages in four regions was used. The regions were 
the Island of São Luís, including the state capital, small municipalities (< 20,000 inhabitants), 
medium-sized municipalities (20,000 to 100,000 inhabitants) and large municipalities except 
for the island (> 100,000 inhabitants). In each stratum, in the first stage, 30 census tracts 
were selected by systematic sampling. In the second stage, 34 households were selected in 
each census tract by systematic sampling. In the third stage, an eligible resident (residing 
for at least six months in the household) aged one year or more was selected by simple 
random sampling using a table of random numbers.
Data Collection, Instruments, and Variables
Trained professionals from the municipal and state health departments were responsible 
for data collection. The starting point (identified with an × on the map) and the geographic 
boundaries of each census tracts were identified using a map provided by the Brazilian 
Institute of Geography and Statistics (IBGE). The first interview was held in the household 
closest to the starting point of each sector. Then, facing that domicile, the interviewer walked 
to the left with his/her right shoulder facing the wall/residences. Without including the 
visited house, the interviewer counted five residences and conducted the next interview 
in the fifth one. If the selected household was empty at the time or the elected person 
did not agree to participate in the survey, the next house to the left (neighbor) of the 
original one was taken as a replacement. If that house was also empty or if the elected 
person refused to participate the next house to the left was visited. Then the interviewer 
counted five domiciles and conducted the next interview in the fifth house after the 
original one. The team always proceeded to the left in relation to the last surveyed domicile 
and conducted the next interview in the fifth domicile. Non-residential buildings were 
excluded from the count. After completing the tour on the block, the interviewer facing 
the last visited domicile continued to the next adjacent block located to the left, always 
adopting the same strategy.
A questionnaire with closed-ended questions was applied in a face-to-face interview with the 
individual or his/her legal guardian. The questionnaire was composed of sociodemographic 
questions, adherence to NPI, self-reported symptoms, and the use of health services. 
The sociodemographic questions included sex, age group, self-reported skin color/race, 
head of the household’s schooling, monthly family income in Brazilian Reals, and the 
number of the household residents. Head of the household’s schooling was classified 
according to the International Standard Classification of Education (ISCED) 2011 into early 
childhood/primary/lower secondary education (levels 0–2), upper secondary/post-secondary 
non-tertiary education (levels 3–4), and tertiary education and beyond (levels 5–8)22. Skin 
color/race was categorized according to the IBGE and divided into white, brown, or black23.
Adherence to NPI at the beginning of the pandemic and in the last month included social 
distancing (yes, if the person never leaves home or seldom goes out, with a maximum 
of one outing every fifteen days, and no otherwise), wearing of face masks (yes, if the 
individual uses a mask on all exits and does not remove or seldom removes the mask 
from the face, and no otherwise), hand hygiene (yes, if the person sanitizes the hands 
more than six times per turn with soap or an alcohol gel, and no otherwise), and physical 
distancing (yes, if the individual never or hardly ever comes within 1.5 m of other people, 
and no otherwise). 
A self-reported symptom rating, adapted from Pollán et al. (2020)11 was used and the persons 
were classified into asymptomatic; oligosymptomatic: the presence of one to two symptoms 
without anosmia/hyposmia or ageusia/dysgeusia; and symptomatic: anosmia/hyposmia or 
ageusia/dysgeusia or more than two symptoms including fever, chills, sore throat, cough, 
dyspnea, diarrhea, nausea/vomiting, headache, fatigue, and myalgia.
Questions on the use of health services included if the individual looked for health services, 
received care when seeking health services, was hospitalized for over 24 hours, received a 
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medical diagnosis of suspected COVID-19, performed RT-PCR for SARS-CoV-2, and performed 
an antibody test– point-of-care/serology for SARS-CoV-2.
Data were abstracted into the Epicollect5 Data Collection mobile application.
SARS-CoV-2 Antibodies Detection
For the qualitative determination of antibodies against SARS-CoV-2, 5.0 ml of whole blood 
was collected, and after centrifugation at 1800 g for 15 min, the serum was obtained. Then, 
a highly sensitive and specific sandwich electrochemiluminescence immunoassay (Elecsys® 
Anti-SARS-CoV-2 assay, Roche Diagnostics) was used to detect IgM and IgG antibodies 
against the SARS-CoV-2 nucleocapsid antigen according to the manufacturer’s instruction 
using a fully automated Cobas® e601 immunoassay analyzer (Roche Diagnostics)24.
Sample Size Calculation
The formula used to determine the sample size in each stratum was given by
n = × P × Q ×N 1 P × QN - 1 CV 2 × P 2 + N - 1
N being the population size in each stratum; P the expected prevalence in the stratum; 
Q=1-P; and CV the coefficient of variation of the prevalence estimates within the stratum. In 
each stratum, the expected prevalence of infection was 20%, and the coefficient of variation 
was 10%. For the final estimate, a design effect of 2 was added. Thus, the minimum number 
of individuals per stratum was 800, totaling 3,200 individuals to compose the sample. 
Predicting losses, the sample size was increased by 25% resulting in 4,000 observations.
Statistical Analysis
The basic sample weight of each selected unit (census sector, household, and individual) was 
estimated separately for each stratum, considering the inverse of the selection probability 
according to the sampling plan specified for the study.
The probability of selection of the census sector “j” in each stratum “i” of the sample is given 
by 30/Si, in which “Si” is the number of census sectors of the stratum “i” in the population 
and the probability of the domicile of the census sector “j” of the stratum “i” being selected 
was obtained from the following expression: 34/Dij, in which “Dij” is the number of domiciles 
in sector “j” of the stratum “i” in the population. The probability of each resident in the 
selected household was given by 1/(number of residents in the household). The number of 
sectors and domiciles was obtained from the 2010 Census of the IBGE. 
Since losses, refusals, and non-responses occurred, the response rate in each stratum was 
also estimated. Considering that there were three stages, the final weight was obtained by 
the product of the basic weight in each stage and the response rate.
All analyses were performed using R version 4.0.2. Weighting factors, clustering, and stratification 
were incorporated into the analyses via the R survey package. Prevalence and 95% confidence 
interval (95%CI) of SARS-CoV-2 infection was obtained according to the sociodemographic 
characteristics, adherence to NPI, self-reported symptoms, and the use of health services. The 
chi-square test, considering the study design, was used to compare the prevalence between 
groups. The McNemar test was used to compare adherence to NPI over time.
The overall and sex- and age-specific IFR were estimated by dividing the estimated number of 
deaths by the estimated proportion of infections obtained by the serological survey multiplied 
by the stratified age and sex population estimates4. The number of deaths that occurred up 
to August 8, 2020 was abstracted from official sources5. The number of deaths occurring 
daily was estimated using Nowcasting by Bayesian Smoothing (NobBS), to consider reporting 
delays. This procedure incorporates uncertainty both in the delay distribution and in the 
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evolution of the pandemic curve over time, resulting in smooth, time-correlated estimates 
of the number of deaths25. Simulations were conducted using the NobBS R package, with 
a negative binomial model with an adaptation phase of 10,000 iterations and a burn-in of 
10,000 iterations for estimating deaths in the state of Maranhão, and the same parameters 
with 5,000 iterations for the São Luís Island. Furthermore, since there is underascertainment 
of deaths due to COVID-19, IFR was also estimated considering excess mortality due to 
all natural causes. Excess deaths were abstracted from the Panel to analyze the excess 
mortality from natural causes in Brazil in 202026. Data on excess mortality is only available 
stratified by sex and two age groups (< 60 and ≥ 60 years)27. The 95% confidence intervals for 
the IFR were based on delta methods accounting for the binomial variance in the numerator 
(number of deaths) and the estimated variance, considering the complex sampling design 
in the denominator (number of infections)28.
Ethical Approval
Ethical approval was obtained from the Research Ethics Committee of the Carlos Macieira 
Hospital of the Maranhão State Health Secretariat under CAAE number 34708620.2.0000.8907. 
An informed consent form was provided by the participants or the parents/legal guardians.
RESULTS
A total of 3,289 individuals (80.6%) agreed to participate in our study. After the exclusion 
of samples with insufficient material or hemolyzed samples, and cases, in which it was not 
possible to link the result of the examination with the person, 3,156 participants had their blood 
samples analyzed (77.4%). Comparing the sampling with the population distribution (age and 
sex estimates for 2020), men and people of working age were underrepresented in the sample.
Seroprevalence of total antibodies against SARS-CoV-2 was 40.4% (95%CI 35.6-45.3) in the 
state of Maranhão, Brazil. Seroprevalence varied by region, from 20.0% in small municipalities 
with < 20,000 inhabitants, reaching 47.6% in medium-sized municipalities from 20,000 to 
100,000 inhabitants (p = 0.006). Seroprevalence in the São Luís Island, including the capital 
city, was 38.9%. There were no significant differences in the prevalence according to the 
sex or age group (Table 1).
White people had a lower point prevalence (20.0%) when compared with both brown (41.3%) 
and black people (49.2%), but of borderline significance (between 0.05 and 0.10). Persons 
with tertiary education had a lower prevalence of infection (27.5%) than their counterparts 
(p = 0.011). Although point prevalence was lower among those with a monthly family income 
above 3,000 Brazilian Reals, the difference did not reach a significant level. Infection rates 
were higher among households with three dwellers (44.9%) (p = 0.028) (Table 1).
Population adherence to NPI to contain the COVID-19 pandemic were mostly higher at the 
beginning of the pandemic than in the last month. Social distancing decreased from 52.7% 
to 37.4% (p < 0.001). The percentage of wearing a face mask decreased from 61.4% to 55.5% 
(p < 0.001). Differences in infection rates between those that maintained social distancing 
and those that did not were evident both at the beginning of the pandemic (36.4% vs 45.0%, 
p = 0.020) and in the last month (34.0% vs 44.3%, P = 0.015). SARS-CoV-2 infection rates were 
significantly lower in the last month among mask wearers and those that maintained a 
distance of at least 1.5 m from other people compared to their counterparts (p = 0.036 for 
mask-wearing and p = 0.030 for physical distancing) (Table 2).
Differences in the self-reporting symptoms were highly significant comparing those 
with and without antibodies to SARS-CoV-2. Among the infected, 62.2% had more than 
three symptoms, whereas 26.0% were asymptomatic and, 11.8% reported only one or two 
symptoms (oligosymptomatic). The predominant symptoms among those who tested positive 
for SARS-CoV-2 were anosmia/hyposmia (49.5%), ageusia/dysgeusia (47.7%), fever (45.6%), 
headache (45.4%), myalgia (43.6%), and fatigue (41.1%) (Table 3).
6
Population-based seroprevalence of SARS-CoV-2 Silva AAM et al.
https://doi.org/10.11606/s1518-8787.2020054003278
Among the infected, 27.6% sought medical care and most received it. A small minority 
(1.9%) was hospitalized for over 24 hours, 13.3% were told they were suspected of having 
COVID-19, 4.3% performed an RT-PCR for SARS-CoV-2, and 13.5% performed a point of care 
test/serology for SARS-CoV-2 (Table 4).
The IFR was 0.14% for the state of Maranhão, and 0.28% for the São Luís Island, considering 
reporting delays by NobBS. IFR was higher for men and older adults (Table 5). The estimate 
doubled to 0.28%, using data on excess mortality (Table 6). The case reporting rate was 
4.5% for the state of Maranhão, and 3.4% for the São Luís Island, resulting in a ratio of the 
estimated infection to the reported cases as 22.2 for the state of Maranhão, and 29.9 for the 
São Luís Island (data not shown).
Table 1. Prevalence of antibodies against SARS-CoV-2 by region, sex, age group, race, schooling, family income and number of residents, 
state of Maranhão, Brazil, 2020.




% infected weighted 
(95%CI)
p
Total 3156 100.0 100.0 1167 40.4 (35.6–45.3)
Region 0.006
São Luís Island including the capital 737 25.5 20.2 349 38.9 (24.5–53.2)
Municipalities with < 20,000 inhabitants 754 20.0 21.4 215 31.0 (24.3–37.8)
Municipalities with 20,000 to 100,000 inhabitants 839 41.6 45.1 346 47.6 (42.0–53.1)
Municipalities with > 100,000 inhabitants 826 12.9 13.2 257 35.2 (26.1–44.3)
Sex 0.134
Male 1200 37.1 49.1 426 37.2 (31.8–42.6)
Female 1956 62.9 50.9 741 42.4 (36.1–48.6)
Age group (years)a 0.230
1–9 124 5.2 16.5 49 42.6 (33.8–51.3)
10–19 330 14.7 18.6 125 43.0 (33.5–52.4)
20–29 427 12.5 18.0 184 49.2 (41.1–57.3)
30–39 475 15.0 16.0 170 44.4 (37.4–51.4)
40–49 502 16.3 12.0 191 32.2 (23.4–41.0) 
50–59 501 14.6 8.5 168 39.1 (32.1–46.1)
60–69 409 11.7 5.7 144 40.3 (29.1–51.4)
≥ 70 386 9.8 4.8 136 34.3 (25.7–42.9)
Self-reported skin color/raceb 0.080
White 590 20.0 - 200 32.2 (20.1–44.4) 
Brown 2100 67.4 - 767 41.3 (37.1–45.4) 
Black 396 12.6 - 177 49.1 (42.3–55.9) 
Head of the household’s schooling (years)* 0.011
Primary/Lower secondary 1369 37.7 - 487 40.9 (35.4–46.4)
Upper secondary 1251 41.9 - 512 46.2 (41.3–51.2)
Tertiary 517 20.4 - 161 27.5 (16.9–38.1)
Monthly family income (Brazilian Real)a,c 0.101
< 1000 607 17.7 - 222 40.8 (34.6–46.9)
1000 a < 2000 1405 42.5 - 540 45.9 (41.0–50.9)
2000 a < 3000 617 20.8 - 243 42.9 (35.7–50.2)
> 3000 493 19.0 - 155 27.9 (17.0–38.9)
Number of residents 0.028
1 386 3.9 - 122 35.4 (27.2–43.6)
2 840 15.7 - 302 37.7 (32.0–43.5)
3 739 21.2 - 297 44.9 (40.0–49.8)
4 628 28.0 - 234 38.8 (29.0–48.5)
≥ 5 563 31.2 - 212 40.9 (33.5–48.3)
95%CI: 95% confidence interval; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.
a Numbers did not add up to total because of missing values.
b Yellow and indigenous were excluded because they were too few for a meaningful analysis.
c 1 Brazilian Real (R$) is equivalent to approximately US$ 5.60 US dollars.
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Table 2. Prevalence of antibodies against SARS-CoV-2 according to adherence to non-pharmaceutical 
interventions at the beginning of the pandemic and in the last month, state of Maranhão, Brazil, 2020.
Non-pharmaceutical interventions n % weighted f infected
% infected weighted 
(95%CI)
p
At the beginning of the pandemic
Social distancing 0.020
No 1392 47.3 557 45.0 (39.3–50.6)
Yesa 1764 52.7 610 36.4 (30.6–42.2)
Wearing of face masks 0.395
No 1153 38.6 423 42.3 (35.8–48.8)
Yesb 2003 61.4 744 39.3 (33.7–44.8)
Hand hygiene 0.285
No 1455 47.9 554 42.7 (36.9–48.4)
Yesc 1701 52.1 613 38.4 (31.9–44.9)
Physical distancing 0.065
No 1548 52.2 602 43.5 (37.6–49.4)
Yesd 1608 47.8 565 37.1 (31.4–42.8)
Last month
Social distancing 0.015
No 1875 62.6 757 44.3 (39.6–49.0)
Yesa 1281 37.4 410 34.0 (26.5–41.4)
Wearing of face masks 0.036
No 1310 44.5 517 45.9 (40.6–51.3)
Yesb 1846 55.5 650 36.0 (29.1–43.0)
Hand hygiene 0.095
No 1557 51.6 612 44.4 (39.1–49.7)
Yesc 1599 48.4 555 36.2 (28.7–43.8)
Physical distancing 0.030
No 1817 61.0 710 43.3 (38.0–48.6)
Yesd 1339 39.0 457 35.9 (29.7–42.2)
95%CI: 95% confidence interval; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.
a Never leaves home or seldom goes out, with a maximum of one outing every fifteen days.
b Uses mask on all exits and does not remove or seldom removes the mask from the face.
c Sanitizes the hands ≥ 6 times per turn (morning, afternoon, and night) with soap or alcohol gel.
d Never or hardly ever comes within 1.5 m of other people.
Table 3. Reported symptoms of SARS-CoV-2 infection, state of Maranhão, Brazil, 2020.
Variables
Non-infected (n = 1,989) Infected (n = 1,167)
p
n % weighted (95%CI) n % weighted (95%CI)
Self-reported symptom ratinga < 0.001
Asymptomatic 1104 52.1 (47.3–56.9) 320 26.0 (21.0–31.0)
Oligosymptomatic (1 to 2 symptoms) 427 22.8 (18.8–26.7) 134 11.8 (8.9–14.6)
Symptomatic (≥ 3 symptoms) 458 25.2 (21.8–28.5) 713 62.2 (56.2–68.3)
Self-reported symptoms
Fever 296 16.7 (13.1–20.4) 494 45.6 (39.9–51.3) < 0.001
Shivers 253 13.7 (9.9–17.6) 379 34.3 (29.5–39.2) < 0.001
Sore throat 345 18.3 (14.7–22.0) 378 34.5 (30.1–39.0) < 0.001
Cough 356 17.6 (13.7–21.5) 369 33.1 (29.7–36.5) < 0.001
Dyspnoea 184 10.9 (8.4–13.4) 209 18.6 (15.0–22.2) 0.001
Runny nose 370 19.2 (16.0–22.3) 364 32.2 (28.0–36.5) < 0.001
Palpitations 204 9.5 (7.1–11.9) 178 15.6 (12.1–19.2) < 0.001
Anosmia/Hyposmia 117 7.3 (5.0–9.6) 547 49.5 (42.5–56.5) < 0.001
Ageusia/Dysgeusia 133 8.2 (5.8–10.5) 535 47.7 (40.4–54.9) < 0.001
Diarrhoea 186 8.9 (6.5–11.2) 210 18.1 (15.1–21.2) < 0.001
Nausea/vomiting 146 7.2 (5.2–9.2) 177 15.1 (12.0–18.2) < 0.001
Headache 509 27.5 (22.7–32.2) 491 45.4 (38.7–52.0) < 0.001
Abdominal pain 201 10.8 (7.7–13.9) 196 19.8 (14.5–25.1) 0.009
Myalgia 368 17.9 (14.0–21.8) 485 43.6 (36.8–50.3) < 0.001
Fatigue 333 17.1 (13.0–21.3) 449 41.1 (34.5–47.7) < 0.001
Loss of appetite 217 11.1 (8.2–14.0) 396 35.2 (29.2–41.2) < 0.001
95%CI: 95% confidence interval; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.
a Asymptomatic: no symptoms; oligosymptomatic: presence of 1 to 2 symptoms without anosmia/hyposmia or 
ageusia/dysgeusia; symptomatic: anosmia/hyposmia or ageusia/dysgeusia or more than 2 symptoms including 
fever, chills, sore throat, cough, dyspnea, diarrhea, nausea/vomiting, headache, fatigue, and myalgia.
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Table 4. Use of health services by individuals with SARS-CoV-2 antibodies, state of Maranhão, Brazil, 2020.
Variables n % 95%CI
Looked for health service 
No 888 72.4 64.6–80.3
Yes 279 27.6 19.7–35.4
Received care when sought health service
Yes 239 19.0 14.9–23.0
No 40 8.6 0.0–18.1
Did not look for health service 888 72.4 64.6–80.3
Hospitalized for over 24 hours 
No  1148 98.1 96.9–99.2
Yes 19 1.9 0.8–3.1
Received a medical diagnosis of suspected COVID-19
No 1014 86.7 83.1–90.2
Yes  153 13.3 9.8–16.9
Performed RT-PCR for SARS-CoV-2
No 1123 95.7 93.5–98.0
Yes  44 4.3 2.0–6.5
Performed antibody test (point-of-care/serology) for SARS-CoV-2 
No 1019 86.5 82.8–90.1
Yes  148 13.5 9.9–17.2
Total 1167 100.0
95%CI: 95% confidence interval; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.
Table 5. Estimated number of infections, deaths, and infection fatality rates of SARS-CoV-2 by sex and 
age groups, state of Maranhão and São Luís island, Brazil, 2020.
Sex Age Group, years
Estimated number 
of infections
Number of deaths 
(estimated by nowcasting)
Infection fatality rate, 
% (95%CI)
Male
0–9 274,241 8 0.00 (0.00–0.01)
10–19 236,559 12 0.00 (0.00–0.01)
20–29 303,111 21 0.01 (0.00–0.01)
30–39 198,478 76 0.04 (0.03–0.05)
40–49 100,908 150 0.15 (0.10–0.21)
50–59 101,695 274 0.27 (0.18–0.40)
60–69 64,637 584 0.90 (0.68–1.20)
≥ 70 67,000 1381 2.06 (1.56–2.72)
Total 1,299,992 2506 0.19 (0.17–0.22)
Female
0–9 228,212 14 0.01 (0.00–0.01)
10–19 323,171 5 0.00 (0.00–0.00)
20–29 320,049 16 0.01 (0.00–0.01)
30–39 282,436 56 0.02 (0.01–0.03)
40–49 155,868 81 0.05 (0.04–0.08)
50–59 132,770 163 0.12 (0.09–0.16)
60–69 94,033 345 0.37 (0.26–0.52)
≥ 70 48,838 898 1.84 (1.25–2.69)
Total 1,533,005 1579 0.10 (0.09–0.12)
Overall
0–9 500,448 22 0.00 (0.00–0.01)
10–19 567,266 16 0.00 (0.00–0.00)
20–29 628,088 37 0.01 (0.00–0.01)
30–39 505,975 132 0.03 (0.02–0.03)
40–49 275,270 231 0.08 (0.06–0.11)
50–59 237,395 437 0.18 (0.15–0.22)
60–69 162,429 930 0.57 (0.43–0.76)
≥ 70 116,065 2279 1.96 (1.53–2.52)
Total 2,877,454 4085 0.14 (0.13–0.16)
São Luís Island
Overall Total 556,611 1544 0.28 (0.19–0.40)
IFR: infection fatality rate; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.
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Figure 1 shows dates of introduction of compulsory NPI, the weekly number of deaths by 
dates of occurrence and reporting and estimates of the weekly number of deaths based on 
NobBS, considering reporting delays. The pandemic peaked from May 17, 2020 to May 23, 
2020 in the state of Maranhão and from May 3, 2020 to May 9, 2020 in the São Luís Island 
(Figure 2). Since then, the number of deaths has been decreasing, and economic activity has 
been gradually increasing whereas most restrictions, apart from banning mass gatherings 
and opening of public schools and universities, have been eased. Nearly three months since 
the beginning of the relaxation of social distancing, and despite increasing community 
mobility, reported deaths analyzed by date of occurrence remain low.
Table 6. Estimated number of infections, excess deaths, and infection fatality rates of SARS-CoV-2 by 











Number of deaths (estimate 
based on excess deaths due 
to natural causes)a
Infection fatality rate, 
% (95%CI)
Male
0–59 36.38 (30.54–42.22) 1,149,733 1366 0.12 (0.10–0.14)
≥ 60 39.85 (32.74–46.95) 133,937 3903 2.91 (2.43–3.49)
Total 37.18 (31.81–42.55) 1,299,992 5270 0.41 (0.35–0.47)
Female
0–59 44.05 (38.71–49.40) 1,415,266 563 0.04 (0.03–0.05)
≥ 60 36.02 (24.46–47.58) 146,117 2278 1.56 (1.13–2.15)
Total 42.37 (36.11–48.63) 1,533,005 2840 0.19 (0.16–0.22)
Overall
0–59 41.26 (36.84–45.69) 2,629,556 1929 0.07 (0.07–0.08)
≥ 60 37.54 (29.24–45.85) 278,482 6181 2.22 (1.78–2.77)
Total 40.44 (35.57–45.32) 2,877,454 8110 0.28 (0.25–0.32)
IFR: infection fatality rate; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.
a Fonte: Conselho Nacional de Secretários de Saúde. Painel de análise do excesso de mortalidade por causas 
naturais no Brasil em 2020. Brasília, DF: CONASS; 2020 [cited 2020 Sept 21]. Available from: https://www.
conass.org.br/indicadores-de-obitos-por-causas-naturais/
Figure 1. Weekly number of deaths by occurrence and reporting date, and estimated by Bayesian nowcasting from March 15 to September 
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DISCUSSION
The population-based seroprevalence of SARS-CoV-2 in the state of Maranhão, Brazil was 
40.4%. We believe this is the first population-based study to report a prevalence rate in this 
range, for an area as big as Italy.
Over 90% of all infected people develop detectable antibodies against SARS-CoV-2 two 
weeks after infection29. Moreover, SARS-CoV-2 leads to robust memory T cell responses, 
suggesting that infection may at least prevent subsequent severe disease30. Furthermore, 
cross-reactivity between SARS-CoV-2 and coronaviruses that cause the common cold 
may elicit additional protection against infection31. Due to all these factors and based on a 
high seroprevalence of 40.4% achieved in the survey, our data suggests that the local herd 
immunity threshold may have been reached or might be reached soon, depending on the 
patterns of heterogeneity in susceptibility or exposure to infection7,8.
Nevertheless, the achievement of herd immunity will not be sustained if protection wanes32. 
Thus, durable immunity may not be attained before vaccination, and consequently, the 
population would remain susceptible to future recurrent outbreaks6.
In our study, we used the Elecsys® Anti-SARS-CoV-2 electrochemiluminescence immunoassay, 
which presented a high specificity rate of 99.7% (95%CI 99.2-100.0) and a positive predictive value 
(PPV) of 97.4% with a 10% seroprevalence rate33. Electrochemiluminescence immunoassays 
have been shown to present higher sensitivity than lateral flow immunoassays34. Some 
existing lateral f low immunoassays do not attain an ideal performance to be used in 
seroprevalence surveys, especially if they are used with finger-prick35. Therefore, since the 
test we used is more sensitive and specific, we could detect a higher percentage of people 
with antibodies against SARS-CoV-2 with few false-positive results. The distribution and 
percentage of self-reported symptoms among the infected in our survey were similar to what 
has been reported by others9,11,36, providing further evidence that a high false-positive rate 
in our study is unlikely. However, a negative Roche’s Anti-SARS-CoV-2 serology assay does 
not rule out infection37. Moreover, sensitivity may decline over time due to seroreversion38. 
Therefore, we may have underascertained the true SARS-CoV-2 infection rate.
Figure 2. Weekly number of deaths by occurrence and reporting date, and estimated by Bayesian nowcasting from March 15 to September 
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We could not find evidence that infection rates differ by sex, age group, skin color, or income; 
however, given the survey’s complex sampling design, our sample size lacked the statistical 
power to answer these questions. The infection rates were lower among those with tertiary 
education, in agreement with the São Paulo study39.
Infection rates were lower among mask wearers and among those that maintained social 
and physical distancing, suggesting that the use of face masks40 and social41,42 and physical 
distancing40 were necessary to prevent further infections and deaths. However, adherence 
to NPI to curb the COVID-19 pandemic tended to diminish.
Infected people were mostly symptomatic (62.2%), and anosmia/hyposmia and ageusia/
dysgeusia were the two most reported symptoms. Most cases were mild. These findings 
are in agreement with recent studies19,36.
Our estimate of the IFR for the state of Maranhão was lower than the rate (0.71%) estimated 
for Brazil9, the 0.90% estimate described for the UK36 and the combined estimate of 0.68% 
from a meta-analysis by Meyerowitz-Katz et al. (2020)18, but more in line with the 0.24% 
combined estimate obtained by Ioannidis (2020)10 and with the range of 0.30%-0.50% 
estimated by Bayesian Network Analysis16. Variations in IFR may be due to differences in 
the testing capacity, age structures, selective testing of high-risk populations, patterns of 
how deaths are attributed to COVID-196, and strain on the health services43. Therefore, 
IFR is likely to vary across populations. However, the IFR in Maranhão is one of the lowest 
reported to date10, even after considering reporting delays and excess deaths.
In our study, the case reporting rate was 4.5% for the state of Maranhão and 3.4% for the São 
Luís Island, resulting in a ratio of the estimated infection to the reported cases as 22.2 for 
the state of Maranhão and 29.9 for the São Luís Island. These ratios were higher than the 
value of 10.3 reported for Brazil9.
Our study has strong points: it is population-based, had a high response rate of 77.4%, and 
the use of a serum electrochemiluminescence immunoassay testing instead of a lateral 
f low immunoassay with finger-prick. There are some limitations: for some estimates, 
the confidence intervals were wide, and thus our power to detect statistically significant 
associations was lower than that desired; some population groups (men and people of 
working age) were underrepresented in our sample.
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